Fig. 5

Impact of SMC, MDA, and MTAT campaigns depends on campaign timing and coverage. a Top: daily count of adult vectors and EIR. Bottom: clinical cases averted during the year after the first round of drugs distributed as compared to a baseline scenario with no drug campaigns. SMC, MDA and MTAT campaigns were simulated with 50% coverage. See “Methods” section for details on how drug campaigns were configured. Mean and standard deviation of 50 stochastic realizations are shown for each campaign start date. Arrows indicate the campaign start date that results in the maximum number of clinical cases averted for each campaign type. b Cases averted, number of tests and treatments distributed, and cases averted per test or treatment when each drug campaign type is distributed at optimum timing, at 50% coverage. c Cases averted by age group (under 5 years, 5 to 10 years, over 10 years) by campaign type and coverage achieved when each drug campaign type is distributed at optimum timing